To investigate the incidence rate, risk factors, and final outcomes of patients with age-related macular degeneration
(AMD) who have experienced vision loss
despite periodic aflibercept
Subjects with treatment-naive AMD were prospectively recruited and treated with three monthly injections followed by two monthly injections of aflibercept
. The incidence rate and risk factors of more than two lines of vision loss
at any visit were investigated.
We included 196 eyes of 196 patients. Vision loss
was observed in 16 patients (8.2%). Eleven of 16 patients developed vision loss
during the initial 3 months (68.8%). Vision loss
remained in 11 eyes (68.8%) at the final visit. The maximum pigment epithelium detachment
(PED) height (odds ratio = 1.46 for a 100-μ
m increase in the PED height) and disruption of the external limiting membrane (odds ratio = 4.45) were identified as risk factors for developing vision loss
on logistic regression analysis.
The incidence rate of vision loss
treatment was relatively low. Identifying high-risk patients, those with a high PED height and disruption of the external limiting membrane, would be helpful in ensuring appropriate informed consent before treatment. Further studies are needed to establish optimal treatment for these patients.